-
摘要: 双表型肝细胞癌（dual-phenotype hepatocellular carcinoma，DPHCC）是近年报道的肝细胞癌（hepatocellular carcinoma，HCC）的一种新亚型，以组织学上为典型的肝细胞癌但同时表达肝细胞癌和肝内胆管癌（intrahepatic cholangiocarcinoma，ICC）的基因标志物为特征，因其具有HCC和ICC的双重生物学行为，恶性程度更高，临床预后差，因而正确诊断十分重要。CK19是DPHCC诊断的重要标志物之一，可以通过多种途径参与DPHCC的发生和恶性生物学行为的调控。本文拟从DPHCC的临床病理特点、免疫组织化学标记、组织起源发生等方面对DPHCC的研究进展进行综述。Abstract: Dual-phenotype hepatocellular carcinoma (DPHCC) is a novel subtype of hepatocellular carcinoma (HCC). DPHCC presents the classical morphology of HCC but simultaneously expresses the biomarkers of HCC and intrahepatic cholangiocarcinoma (ICC). Accurate diagnosis of DPHCC is necessary because of its combined biological behaviors of HCC and ICC, highly malignant degree, and infaust clinical prognosis. CK19 is an important marker of DPHCC and regulates the clonal origin and biological behavior of DPHCC in various pathways. In this paper, we reviewed the research progress of DPHCC focusing mainly on its clinicopathological features, immunohistochemical biomarkers, and histogenesis.
-
Key words:
- DPHCC /
- diagnosis /
- CK19 /
- histogenesis /
- tumor heterogeneity
-
表 1 DPHCC、HCC、ICC和CHC的诊断和鉴别诊断要点
Table 1. Diagnostic and differential diagnosis of DPHCC, HCC, ICC, and CHC
-
[1] Lu XY, Xi T, Lau WY, et al.Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior[J].Ann Surg Oncol, 2011, 18(8):2210-2217. doi: 10.1245/s10434-011-1585-7 [2] Cong WM, Bu H, Chen J, et al.Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update[J].World J Gastroenterol, 2016, 22(42):9279-9287. doi: 10.3748/wjg.v22.i42.9279 [3] Cong WM, Wu MC.New insights into molecular diagnostic pathology of primary liver cancer: Advances and challenges[J].Cancer Lett, 2015, 368(1):14-19. doi: 10.1016/j.canlet.2015.07.043 [4] 丛文铭. 双表型肝癌[M]//肝胆肿瘤外科病理学.北京:人民卫生出版社,2015:318-319.Cong WM.Dual-phenotype hepatocellular carcinoma[M]//Surgical Pathology of Hepatobiliary Tumors.Beijing: People's Medical Publishing House, 2015:318-319. [5] Theise ND, Nakashima O, Park YN, et al.Combined hepatocellularcholangiocarcinoma[M]//Bosman FT, Carneiro F, Hruban RH, Theise ND eds.WHO classification of tumours of the digestive system.Lyon: IARC Press.2010:225-227. [6] Kim H, Choi GH, Na DC, et al.Human hepatocellular carcinomaswith "Stemness"-related marker expression: keratin 19 expression and a poor prognosis[J].Hepatology, 2011, 54(5):1707-1717. doi: 10.1002/hep.24559 [7] Kawai T, Yasuchika K, Seo S, et al.Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-fluorodeoxyglucose positron emission tomography[J].Clin Cancer Res, 2016, 23(6):1450-1460. doi: 10.1158/1078-0432.CCR-16-0871 [8] Feng J, Zhu R, Chang C, et al.CK19 and Glypican 3 expression profiling in the prognostic indication for patients with HCC after surgical resection[J].PLoS One, 2016, 11(3):e0151501. doi: 10.1371/journal.pone.0151501 [9] Fatourou E, Koskinas J, Karandrea D, et al.Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma[J].Eur J Gastroenterol Hepatol, 2015, 27(9):1094-1102. doi: 10.1097/MEG.0000000000000398 [10] Miltiadous O, Sia D, Hoshida Y, et al.Progenitor cell markers predictoutcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation[J].J Hepatol, 2015, 63(6):1368-1377. doi: 10.1016/j.jhep.2015.07.025 [11] Govaere O, Komuta M, Berkers J, et al.Keratin 19: a key role player in the invasion of human hepatocellular carcinomas[J].Gut, 2014, 63(4):674-685. doi: 10.1136/gutjnl-2012-304351 [12] Kawai T, Yasuchika K, Ishii T, et al.Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma[J].Clin Cancer Res, 2015, 21(13):3081-3091. doi: 10.1158/1078-0432.CCR-14-1936 [13] Takano M, Shimada K, Fujii T, et al.Keratin 19 as a key molecule in progression of human hepatocellular carcinomas through invasionand angiogenesis[J].BMC Cancer, 2016, 16(1):903. doi: 10.1186/s12885-016-2949-y [14] Lanzoni G, Cardinale V, Carpino G.The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration[J].Hepatology, 2016, 64(1):277-286. doi: 10.1002/hep.v64.1 [15] Lu WY, Bird TG, Boulter L, et al.Hepatic progenitor cells of biliary origin with liver repopulation capacity[J].Nat Cell Biol, 2015, 17(8):971-983. doi: 10.1038/ncb3203 [16] Shin S, Upadhyay N, Greenbaum LE, et al.Ablation of Foxl1-Cre-labeled hepatic progenitor cells and their descendants impairs recovery of mice from liver injury[J].Gastroenterology, 2015, 148(1):192-202 e193. doi: 10.1053/j.gastro.2014.09.039 [17] Xue F, Hu L, Ge R, et al.Autophagy-deficiency in hepatic progenitor cells leads to the defects of stemness and enhances susceptibility to neoplastic transformation[J].Cancer Letters, 2016, 371(1):38-47. doi: 10.1016/j.canlet.2015.11.022 [18] Serrano F, García-Bravo M, Blazquez M, et al.Silencing of hepatic fate-conversion factors induce tumorigenesis in reprogrammed hepatic progenitor-like cells[J].Stem Cell Res Ther, 2016, 7:96. doi: 10.1186/s13287-016-0349-5 [19] DePeralta DK, Wei L, Ghoshal S, et al.Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis[J].Cancer, 2016, 122(8):1216-1227. doi: 10.1002/cncr.29912 [20] Lee J-S, Heo J, Libbrecht L, et al.A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells[J].Nat Med, 2006, 12(4):410-416. doi: 10.1038/nm1377 [21] Yu DD, Jing YY, Guo SW, et al.Overexpression of hepatocyte nuclear factor-1beta predicting poor prognosis is associated with biliary phenotype in patients with hepatocellular carcinoma[J].Sci Rep, 2015, 5:13319. doi: 10.1038/srep13319 [22] Liu Y, Cao L, Chen R, et al.Osteopontin promotes hepatic progenitor cell expansion and tumorigenicity via activation of beta-catenin in mice[J].Stem Cells, 2015, 33(12):3569-3580. doi: 10.1002/stem.2072 [23] Govaere O, Wouters J, Petz M, et al.Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche[J].J Hepatol, 2016, 64(3): 609-617. doi: 10.1016/j.jhep.2015.11.011 [24] McGranahan N, Swanton C.Biological and therapeutic impact of intratumor heterogeneity in cancer evolution[J].Cancer Cell, 2015, 27(1):15-26. doi: 10.1016/j.ccell.2014.12.001 [25] Xue R, Li R, Guo H, et al.Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma[J].Gastroenterology, 2016, 150(4):998-1008. doi: 10.1053/j.gastro.2015.12.033 [26] Kowalik MA, Sulas P, Ledda-Columbano GM, et al.Cytokeratin-19positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis[J].Oncotarget, 2015, 6(36):38749-38763. https://www.ncbi.nlm.nih.gov/pubmed/26452031 [27] Lai JP, Conley A, Knudsen BS, et al.Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma[J].Histopathology, 2015, 67(4):442-445 doi: 10.1111/his.2015.67.issue-4 -
点击查看大图
表(1)
计量
- 文章访问数: 66
- HTML全文浏览量: 102
- PDF下载量: 14
- 被引次数: 0
下载:
